Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Suzhafu is a traditional Uighur medicine (a branch of Traditional Chinese Medicine) developed and manufactured by Xinjiang Huakang Pharmaceutical Co., Ltd. It is primarily indicated for the treatment of vitiligo vulgaris, a condition characterized by the loss of skin pigment. Formulated as oral granules, Suzhafu is a multi-component herbal preparation containing ingredients such as *Vernonia anthelmintica*, *Psoralea corylifolia*, *Alpinia officinarum*, *Piper nigrum*, and *Zingiber officinale*. Its therapeutic effect is attributed to its ability to promote blood circulation, regulate immune responses, and stimulate melanocyte activity and tyrosinase expression, thereby facilitating repigmentation of the skin. It is widely used in clinical practice in China, often as part of a comprehensive treatment regimen for vitiligo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on suzhafu granules.